Press Releases Year: - Any -201920182017201620152014 Items per page 102550 Date Title and Summary Additional Formats Toggle SummaryJul 30, 2019 Alder BioPharmaceuticals® to Host Conference Call to Discuss Second Quarter 2019 Financial and Operating Results View HTML Toggle SummaryJul 26, 2019 Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) View HTML Toggle SummaryJul 11, 2019 Alder BioPharmaceuticals® Presents New Data on Migraine-Free Months, Migraine Severity and Quality of Life, Demonstrating Eptinezumab’s Clinical Profile for Migraine Prevention View HTML Toggle SummaryJul 08, 2019 Alder BioPharmaceuticals® to Showcase 14 New Data Presentations Demonstrating Eptinezumab’s Migraine Prevention and Quality of Life Impact at American Headache Society Meeting View HTML Toggle SummaryJun 19, 2019 Alder BioPharmaceuticals® to Webcast Upcoming Breakfast Symposium with Key Opinion Leaders View HTML Toggle SummaryJun 18, 2019 Alder BioPharmaceuticals® to Present at BMO Capital Markets 2019 Prescription for Success Healthcare Conference View HTML Toggle SummaryMay 24, 2019 Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) View HTML Toggle SummaryMay 14, 2019 Alder BioPharmaceuticals® to Present at Two Upcoming May Investor Conferences View HTML Toggle SummaryMay 08, 2019 Alder BioPharmaceuticals® Presents New Analysis of Patient-Reported Outcomes Following Eptinezumab Treatment for Migraine Prevention View HTML Toggle SummaryMay 06, 2019 Alder BioPharmaceuticals® Presents New Data Demonstrating Consistent, Early and Robust Prevention with Eptinezumab for Episodic and Chronic Migraine across Four Clinical Trials View HTML Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next Last page Last
